Project Grant HT94252310376
Award Date
5/1/23
Completion Date
4/30/26
Dollars Obligated
$4.5M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02138, USA
Similar Awards
This $1,148,000 federal Project Grant award from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) was provided to The Trustees of Princeton University to develop novel approaches for combating bacterial infections and antibiotic resistance. The key products and services to be delivered under this 5-year grant include: Utilizing a breakthrough single-cell RNA sequencing technology called M3-SEQ, the researchers will study host-pathogen interactions and dynamics...
This National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I award to Bactria Pharmaceuticals LLC is providing $274,937 to develop therapeutic drugs that restore antibiotic sensitivity in bacteria that cause severe healthcare-associated infections. The goal is to combat antimicrobial resistance in gram-negative pathogens through the use of small molecule efflux pump inhibitors (EPIs). The project involves three key activities: cryo-electron microscopy to understand...
This Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $305,000 to Novaurum Biosciences Incorporated to develop a novel mammalian cell-based nano-biological coating for implantable medical devices. The goal is to address the critical health and economic burden associated with implant-related infections by creating a biocompatible and antimicrobial coating that can limit biofilm formation and protect...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Biotherapeutics, Inc. a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to accelerate the development of a novel, antimicrobial-free therapeutic for Clostridioides difficile infection (CDI). The project aims to conduct head-to-head comparisons of the efficacy of Biotherapeutics' product candidate versus FDA-approved CDI treatments in recurrent mouse models. Key objectives...
This Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, provides $317,029 to Chemia Biosciences, Inc. to develop advanced computational methods and software tools for discovering novel antimicrobial natural products. The project aims to leverage high-throughput mass spectrometry and genome mining techniques to identify and predict the molecular structures of polysaccharides and aminoglycosides - an important class of natural...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) totaling $288,360 to Biological Mimetics, Inc., a biotechnology firm in Frederick, Maryland. The grant funds the development of a novel vaccine candidate against multi-drug resistant Acinetobacter baumannii (MDR-AB), an escalating global health threat. Key objectives include: Identifying and characterizing immunogenic components of MDR-AB that can...
This $802,798 federal Project Grant was awarded on July 2, 2024 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports the development of a novel class of antibiotics called Biamyxins (BMX) that target multidrug-resistant Gram-negative bacterial infections, which are a leading cause of healthcare-associated infections (HAIs) in the U.S. The goal is to identify a lead development candidate...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is for the development of novel antibiotic therapies targeting Clostridioides difficile infection (CDI). The $754,446 award aims to: Optimize a lead series of inhibitors targeting the essential bacterial enzyme FabK, with the goal of improving antimicrobial potency and selectivity against C. difficile. Identify new chemical...
This $2,199,979 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is funding a Phase 1 randomized, placebo-controlled, single ascending dose study to examine the safety, tolerability, and pharmacokinetics of the compound CNP8 in healthy adults. The award recipient, Neomatrix Therapeutics Inc., is a self-certified small disadvantaged business providing biomedical research and advanced wound treatment products and services....
The federal Project Grant award R01AI187556 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $749,417.00 in funding to President and Fellows of Harvard College from November 2024 through October 2029. The research project aims to synthesize and evaluate novel antibiotic compounds targeting the lipoprotein transport pathway in Gram-negative bacteria, including multidrug-resistant E. coli and K....